Tempus AI (NASDAQ:TEM) Stock Price Up 3.8% – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM) shares were up 3.8% on Thursday . The company traded as high as $35.29 and last traded at $35.05. Approximately 1,233,969 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 1,636,523 shares. The stock had previously closed at $33.76.

Analyst Upgrades and Downgrades

TEM has been the topic of several recent research reports. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the company from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital raised their price objective on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Bank of America boosted their target price on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Price Performance

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock has a 50 day simple moving average of $48.93 and a 200-day simple moving average of $46.63.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. This trade represents a 17.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total value of $7,044,568.70. Following the completion of the transaction, the chief executive officer now owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. This represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 845,041 shares of company stock valued at $35,125,473 in the last quarter.

Institutional Investors Weigh In On Tempus AI

Several institutional investors have recently modified their holdings of the business. NEA Management Company LLC bought a new stake in Tempus AI in the 2nd quarter worth approximately $160,048,000. Novo Holdings A S bought a new stake in shares of Tempus AI in the second quarter worth $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in Tempus AI during the second quarter valued at $128,133,000. ARK Investment Management LLC lifted its holdings in Tempus AI by 355.0% in the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after acquiring an additional 1,855,459 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.